Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2010 (2010), Article ID 428253, 14 pages
http://dx.doi.org/10.1155/2010/428253
Review Article

Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives

Department of Internal Medicine, University of Genoa, Room 221, V.le Benedetto XV 6, 16132 Genoa, Italy

Received 1 July 2010; Revised 5 November 2010; Accepted 22 December 2010

Academic Editor: Scott Antonia

Copyright © 2010 Giulia Motta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Kohler and C. Milstein, “Continuous cultures of fused cells secreting antibody of predefined specificity,” Nature, vol. 256, no. 5517, pp. 495–497, 1975. View at Google Scholar · View at Scopus
  2. N. Cooper and D. M. Arnold, “The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases,” British Journal of Haematology, vol. 149, no. 1, pp. 3–13, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. O. J. Finn, “Cancer immunology,” New England Journal of Medicine, vol. 358, no. 25, pp. 2704–2715, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. G. L. Plosker and D. P. Figgitt, “Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia,” Drugs, vol. 63, no. 8, pp. 803–843, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Demidem, T. Lam, S. Alas, K. Hariharan, N. Hanna, and B. Bonavida, “Chimeric anti-CD20 (idec-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs,” Cancer Biotherapy and Radiopharmaceuticals, vol. 12, no. 3, pp. 177–186, 1997. View at Google Scholar · View at Scopus
  6. L. M. Nadler, J. Ritz, and R. Hardy, “A unique cell surface antigen identifying lymphoid malignancies of B cell origin,” Journal of Clinical Investigation, vol. 67, no. 1, pp. 134–140, 1981. View at Google Scholar
  7. M. Petryk and M. L. Grossbard, “Rituximab therapy of B-cell neoplasms,” Clinical Lymphoma, vol. 1, no. 3, pp. 186–194, 2000. View at Google Scholar · View at Scopus
  8. N. M. Almasri, R. E. Duque, J. Iturraspe, E. Everett, and R. C. Braylan, “Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia,” American Journal of Hematology, vol. 40, no. 4, pp. 259–263, 1992. View at Publisher · View at Google Scholar · View at Scopus
  9. J. P. Deans, H. Li, and M. J. Polyak, “CD20-mediated apoptosis: signalling through lipid rafts,” Immunology, vol. 107, no. 2, pp. 176–182, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. J. K. Bubien, L. J. Zhou, P. D. Bell, R. A. Frizzell, and T. F. Tedder, “Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca conductance found constitutively in B lymphocytes,” Journal of Cell Biology, vol. 121, no. 5, pp. 1121–1132, 1993. View at Publisher · View at Google Scholar · View at Scopus
  11. C. A. Walshe, S. A. Beers, R. R. French et al., “Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling,” Journal of Biological Chemistry, vol. 283, no. 25, pp. 16971–16984, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. A. J. Grillo-López, E. Hedrick, M. Rashford, and M. Benyunes, “Rituximab: ongoing and future clinical development,” Seminars in Oncology, vol. 29, no. 1, pp. 105–112, 2002. View at Google Scholar · View at Scopus
  13. S. V. Onrust, H. M. Lamb, and J. A. Balfour, “Rituximab,” Drugs, vol. 58, no. 1, pp. 79–88, 1999. View at Publisher · View at Google Scholar · View at Scopus
  14. M. J. Glennie, R. R. French, M. S. Cragg, and R. P. Taylor, “Mechanisms of killing by anti-CD20 monoclonal antibodies,” Molecular Immunology, vol. 44, no. 16, pp. 3823–3837, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. J. L. Teeling, W. J. M. Mackus, L. J. J. M. Wiegman et al., “The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20,” Journal of Immunology, vol. 177, no. 1, pp. 362–371, 2006. View at Google Scholar · View at Scopus
  16. A. R. Jazirehi and B. Bonavida, “Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention,” Oncogene, vol. 24, no. 13, pp. 2121–2143, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. B. Bonavida, “Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions,” Oncogene, vol. 26, no. 25, pp. 3629–3636, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. A. R. Jazirehi, M. I. Vega, D. Chatterjee, L. Goodglick, and B. Bonavida, “Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, BCL- down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by rituximab,” Cancer Research, vol. 64, no. 19, pp. 7117–7126, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Alas and B. Bonavida, “Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs,” Cancer Research, vol. 61, no. 13, pp. 5137–5144, 2001. View at Google Scholar · View at Scopus
  20. M. I. Vega, A. R. Jazirehi, S. Huerta-Yepez, and B. Bonavida, “Rituximab-induced inhibition of YY1 and Bcl-xL expression in ramos non-Hodgkin's lymphoma cell line via inhibition of NF-{kappa}B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively,” Journal of Immunology, vol. 175, no. 4, pp. 2174–2183, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Huerta-Yepez, M. Vega, A. Jazirehi et al., “Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-κB and inhibition of Bcl- expression,” Oncogene, vol. 23, no. 29, pp. 4993–5003, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Kheirallah, P. Caron, E. Gross et al., “Rituximab inhibits B-cell receptor signaling,” Blood, vol. 115, no. 5, pp. 985–994, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Chen, S. Monti, P. Juszczynski et al., “SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma,” Blood, vol. 111, no. 4, pp. 2230–2237, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Leseux, S. M. Hamdi, T. Al Saati et al., “Syk-dependent mTOR activation in follicular lymphoma cells,” Blood, vol. 108, no. 13, pp. 4156–4162, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. R. M. Young, I. R. Hardy, R. L. Clarke et al., “Mouse models of non-hodgkin lymphoma reveal Syk as an important therapeutic target,” Blood, vol. 113, no. 11, pp. 2508–2516, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. M. R. Smith, “Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance,” Oncogene, vol. 22, no. 47, pp. 7359–7368, 2003. View at Google Scholar · View at Scopus
  27. J. O. Armitage, “How I treat patients with diffuse large B-cell lymphoma,” Blood, vol. 110, no. 1, pp. 29–36, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Marcus, K. Imrie, P. Solal-Celigny et al., “Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma,” Journal of Clinical Oncology, vol. 26, no. 28, pp. 4579–4586, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. W. Hiddemann, M. Kneba, M. Dreyling et al., “Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group,” Blood, vol. 106, no. 12, pp. 3725–3732, 2005. View at Publisher · View at Google Scholar
  30. M. H. J. Van Oers, R. Klasa, R. E. Marcus et al., “Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial,” Blood, vol. 108, no. 10, pp. 3295–3301, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Forstpointner, M. Unterhalt, M. Dreyling et al., “Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG),” Blood, vol. 108, no. 13, pp. 4003–4008, 2006. View at Publisher · View at Google Scholar
  32. M. Herold, A. Haas, S. Srock et al., “Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German study group hematology and oncology study,” Journal of Clinical Oncology, vol. 25, no. 15, pp. 1986–1992, 2007. View at Publisher · View at Google Scholar
  33. D. G. Maloney, A. J. Grillo-López, C. A. White et al., “IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma,” Blood, vol. 90, no. 6, pp. 2188–2195, 1997. View at Google Scholar · View at Scopus
  34. M. Feuring-Buske, M. Kneba, M. Unterhalt et al., “IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German low-grade lymphoma study group,” Annals of Hematology, vol. 79, no. 9, pp. 493–500, 2000. View at Google Scholar · View at Scopus
  35. P. McLaughlin, A. J. Grillo-López, B. K. Link et al., “Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program,” Journal of Clinical Oncology, vol. 16, no. 8, pp. 2825–2833, 1998. View at Google Scholar · View at Scopus
  36. B. Coiffier, E. Lepage, J. Brière et al., “Chop chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large-B-cell lymphoma,” New England Journal of Medicine, vol. 346, no. 4, pp. 235–242, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Pfreundschuh, L. Trümper, A. Österborg et al., “CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group,” Lancet Oncology, vol. 7, no. 5, pp. 379–391, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. T. M. Habermann, E. A. Weller, V. A. Morrison et al., “Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma,” Journal of Clinical Oncology, vol. 24, no. 19, pp. 3121–3127, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. G. Lenz, M. Dreyling, E. Hoster et al., “Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantiy improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG),” Journal of Clinical Oncology, vol. 23, no. 9, pp. 1984–1992, 2005. View at Publisher · View at Google Scholar
  40. T. Robak, A. Dmoszynska, P. Solal-Céligny et al., “Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia,” Journal of Clinical Oncology, vol. 28, no. 10, pp. 1756–1765, 2010. View at Google Scholar · View at Scopus
  41. CLL8- German CLL Study Group.
  42. E. Kimby, M. Bjorkholm, G. Gahrton et al., “Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden,” Annals of Oncology, vol. 5, no. 2, pp. 67–71, 1994. View at Google Scholar · View at Scopus
  43. M. S. Czuczman, R. Weaver, B. Alkuzweny, J. Berlfein, and A. J. Grillo-López, “Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up,” Journal of Clinical Oncology, vol. 22, no. 23, pp. 4659–4664, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. M. S. Czuczman, A. Koryzna, A. Mohr et al., “Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma,” Journal of Clinical Oncology, vol. 23, no. 4, pp. 694–704, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. W. Hiddemann, C. Buske, M. Dreyling et al., “Treatment strategies in follicular lymphomas: current status and future perspectives,” Journal of Clinical Oncology, vol. 23, no. 26, pp. 6394–6399, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. E. Domingo-Domenech, E. González-Borco, C. Estany, A. Sureda, J. Besalduch, and A. F. De Sevilla, “Combined treatment with anti CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas,” Haematologica, vol. 87, no. 11, pp. 1229–1230, 2002. View at Google Scholar · View at Scopus
  47. T. A. Davis, A. J. Grillo-Lopez, C. A. White et al., “Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment,” Journal of Clinical Oncology, vol. 18, no. 17, pp. 3135–3143, 2000. View at Google Scholar · View at Scopus
  48. T. A. Davis, C. A. White, A. J. Grillo-López et al., “Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab,” Journal of Clinical Oncology, vol. 17, no. 6, pp. 1851–1857, 1999. View at Google Scholar · View at Scopus
  49. N. Lamanna, J. G. Jurcic, A. Noy et al., “Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses,” Journal of Clinical Oncology, vol. 27, no. 4, pp. 491–497, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. T. Ahmadi and S. J. Schuster, “Variations on the fludarabine, cyclophosphamide, and rituximab combination in chronic lymphocytic leukemia therapy: what have we learned?” Journal of Clinical Oncology, vol. 27, no. 4, pp. 479–480, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. L. Kunkel, A. Wong, T. Maneatis et al., “Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update,” Seminars in Oncology, vol. 27, no. 6, pp. 53–61, 2000. View at Google Scholar · View at Scopus
  52. D. Bedognetti, G. Zoppoli, C. Massucco et al., “Patients treated with rituximab-containing immunochemotherapy have a significant and prolonged lack of humoral response to influenza vaccine associated with a persistent depletion of b memory cells,” in Blood (ASH Annual Meeting Abstracts), November 2009.
  53. B. D. Cheson and J. P. Leonard, “Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma,” New England Journal of Medicine, vol. 359, no. 6, pp. 613–626, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. S. A. Beers, R. R. French, H. T. C. Chan et al., “Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection,” Blood, vol. 115, no. 25, pp. 5191–5201, 2010. View at Publisher · View at Google Scholar
  55. S. Y. Wang, S. Veeramani, E. Racila et al., “Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model,” Blood, vol. 114, no. 26, pp. 5322–5330, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Rambaldi, M. Lazzari, C. Manzoni et al., “Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma,” Blood, vol. 99, no. 3, pp. 856–862, 2002. View at Publisher · View at Google Scholar · View at Scopus
  57. C. G. A. Price, J. Meerabux, S. Murtagh et al., “The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma,” Journal of Clinical Oncology, vol. 9, no. 9, pp. 1527–1532, 1991. View at Google Scholar · View at Scopus
  58. J. Limpens, R. Stad, C. Vos et al., “Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals,” Blood, vol. 85, no. 9, pp. 2528–2536, 1995. View at Google Scholar · View at Scopus
  59. M. H. van Oers, E. Tönnissen, M. Van Glabbeke et al., “BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study,” Journal of Clinical Oncology, vol. 28, no. 13, pp. 2246–2252, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. N. Mounier, J. Briere, C. Gisselbrecht et al., “Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL),” Blood, vol. 101, no. 11, pp. 4279–4284, 2003. View at Publisher · View at Google Scholar · View at Scopus
  61. N. Mounier, J. Briere, C. Gisselbrecht, F. Reyes, P. Gaulard, and B. Coiffier, “Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma,” Haematologica, vol. 91, no. 5, pp. 715–716, 2006. View at Google Scholar · View at Scopus
  62. T. Kewalramani, A. D. Zelenetz, E. E. Hedrick et al., “High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis,” Blood, vol. 96, no. 7, pp. 2399–2404, 2000. View at Google Scholar · View at Scopus
  63. C. Haioun, E. Lepage, C. Gisselbrecht et al., “Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol—a groupe d'etude des lymphomes de l'adulte study,” Journal of Clinical Oncology, vol. 18, no. 16, pp. 3025–3030, 2000. View at Google Scholar · View at Scopus
  64. A. Nademanee and S. J. Forman, “Role of Hematopoietic Stem Cell Transplantation for Advanced-Stage Diffuse Large Cell B-Cell Lymphoma-B,” Seminars in Hematology, vol. 43, no. 4, pp. 240–250, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. N. L. Berinstein, “Principles of maintenance therapy,” Leukemia Research, vol. 30, no. 1, pp. S3–S10, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. J. D. Hainsworth, S. Litchy, H. A. Burris et al., “Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 20, no. 20, pp. 4261–4267, 2002. View at Publisher · View at Google Scholar · View at Scopus
  67. J. D. Hainsworth, S. Litchy, D. W. Shaffer, L. Van Lackey, M. Grimaldi, and F. A. Greco, “Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma—a randomized phase II trial of the Minnie Pearl Cancer Research Network,” Journal of Clinical Oncology, vol. 23, no. 6, pp. 1088–1095, 2005. View at Publisher · View at Google Scholar · View at Scopus
  68. C. Buske and W. Hiddemann, “Rituximab maintenance therapy in indolent NHL: a clinical review,” Leukemia Research, vol. 30, no. 1, pp. S11–S15, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Ghielmini, S. F. H. Schmitz, S. B. Cogliatti et al., “Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule,” Blood, vol. 103, no. 12, pp. 4416–4423, 2004. View at Publisher · View at Google Scholar · View at Scopus
  70. K. A. Foon and M. J. Hallek, “Changing paradigms in the treatment of chronic lymphocytic leukemia,” Leukemia, vol. 24, no. 3, pp. 500–511, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. H. Schulz, S. K. Klein, U. Rehwald et al., “Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia,” Blood, vol. 100, no. 9, pp. 3115–3120, 2002. View at Publisher · View at Google Scholar · View at Scopus
  72. N. Lamanna, M. Kalaycio, P. Maslak et al., “Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia,” Journal of Clinical Oncology, vol. 24, no. 10, pp. 1575–1581, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. T. Robak, P. Smolewski, B. Cebula, O. Grzybowska-Izydorczyk, and J. Z. Błoński, “Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia,” European Journal of Haematology, vol. 79, no. 2, pp. 107–113, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Hallek, G. Fingerle-Rowson, and A.-M. Fink, “First-line treatment with fludarabine (f), cyclophosphamide (c), and rituximab (r) (fcr) improves overall survival (os) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (cll): results of a randomized phase iii trial on behalf of an international group of investigators and the german cll study group,” Blood, vol. 114, 2009. View at Google Scholar
  75. M. J. Keating, S. O'Brien, M. Albitar et al., “Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia,” Journal of Clinical Oncology, vol. 23, no. 18, pp. 4079–4088, 2005. View at Publisher · View at Google Scholar · View at Scopus
  76. C. S. Tam, S. O'Brien, W. Wierda et al., “Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia,” Blood, vol. 112, no. 4, pp. 975–980, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. W. Wierda, S. O'Brien, S. Wen et al., “Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia,” Journal of Clinical Oncology, vol. 23, no. 18, pp. 4070–4078, 2005. View at Publisher · View at Google Scholar · View at Scopus
  78. P. V. Beum, M. A. Lindorfer, and R. P. Taylor, “Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving,” Journal of Immunology, vol. 181, no. 4, pp. 2916–2924, 2008. View at Google Scholar · View at Scopus
  79. A. D. Kennedy, P. V. Beum, M. D. Solga et al., “Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia,” Journal of Immunology, vol. 172, no. 5, pp. 3280–3288, 2004. View at Google Scholar · View at Scopus
  80. P. V. Beum, A. D. Kennedy, and R. P. Taylor, “Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas,” Journal of Immunological Methods, vol. 289, no. 1-2, pp. 97–109, 2004. View at Publisher · View at Google Scholar · View at Scopus
  81. R. Shimizu, J. Kikuchi, T. Wada, K. Ozawa, Y. Kano, and Y. Furukawa, “HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells,” Leukemia, vol. 24, no. 10, pp. 1760–1768, 2010. View at Publisher · View at Google Scholar
  82. C. Henry, M. Deschamps, P. S. Rohrlich et al., “Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance,” Blood, vol. 115, no. 12, pp. 2420–2429, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. R. Bhat and C. Watzl, “Serial killing of tumor cells by human natural killer cells—enhancement by therapeutic antibodies,” PLoS ONE, vol. 2, no. 3, article no. e326, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. J. A. Bowles and G. J. Weiner, “CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells,” Journal of Immunological Methods, vol. 304, no. 1-2, pp. 88–99, 2005. View at Publisher · View at Google Scholar · View at Scopus
  85. L. Fischer, O. Penack, C. Gentilini et al., “The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells,” Experimental Hematology, vol. 34, no. 6, pp. 753–759, 2006. View at Publisher · View at Google Scholar · View at Scopus
  86. J. G. Berdeja, A. Hess, D. M. Lucas et al., “Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab,” Clinical Cancer Research, vol. 13, no. 8, pp. 2392–2399, 2007. View at Publisher · View at Google Scholar · View at Scopus
  87. H. Wang, Y. Liu, Z. Y. Li, X. Fan, A. Hemminki, and A. Lieber, “A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy,” Blood, vol. 115, no. 3, pp. 592–600, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. F. Sato, A. Ito, T. Ishida et al., “A complement-dependent cytotoxicity-enhancing anti-CD20 antibody mediating potent antitumor activity in the humanized NOD/Shi-scid, IL- 2Rγnull mouse lymphoma model,” Cancer Immunology, Immunotherapy, vol. 59, no. 12, pp. 1791–1800, 2010. View at Publisher · View at Google Scholar
  89. M. P. Chao, A. A. Alizadeh, C. Tang et al., “Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma,” Cell, vol. 142, no. 5, pp. 699–713, 2010. View at Publisher · View at Google Scholar
  90. C. Xuan, K. K. Steward, J. M. Timmerman, and S. L. Morrison, “Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma,” Blood, vol. 115, no. 14, pp. 2864–2871, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. B. Li, L. Zhao, H. Guo et al., “Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma,” Blood, vol. 114, no. 24, pp. 5007–50515, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. R. Stein, Z. Qu, S. Chen et al., “Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma,” Clinical Cancer Research, vol. 10, no. 8, pp. 2868–2878, 2004. View at Publisher · View at Google Scholar · View at Scopus
  93. S. Maddipatla, F. J. Hernandez-Ilizaliturri, J. Knight, and M. S. Czuczman, “Augmented antitumor activity against b-cell lymphoma by a combination of monoclonal antibodies targeting trail-r1 and cd20,” Clinical Cancer Research, vol. 13, no. 15, pp. 4556–4564, 2007. View at Publisher · View at Google Scholar · View at Scopus
  94. E. Tobin, G. L. DeNardo, N. Zhang, A. L. Epstein, C. Liu, and S. DeNardo, “Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines,” Leukemia and Lymphoma, vol. 48, no. 5, pp. 944–956, 2007. View at Publisher · View at Google Scholar · View at Scopus
  95. E. A. Rossi, D. M. Goldenberg, T. M. Cardillo, W. J. McBride, R. M. Sharkey, and C. H. Chang, “Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 18, pp. 6841–6846, 2006. View at Publisher · View at Google Scholar · View at Scopus
  96. E. A. Rossi, D. M. Goldenberg, T. M. Cardillo, R. Stein, and C. H. Chang, “Hexavalent bispecific antibodies represent a new class of anticancer therapeutics—1. Properties of anti-CD20/CD22 antibodies in lymphoma,” Blood, vol. 113, no. 24, pp. 6161–6171, 2009. View at Publisher · View at Google Scholar · View at Scopus
  97. E. A. Rossi, D. M. Goldenberg, T. M. Cardillo, R. Stein, Y. Wang, and C. H. Chang, “Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics,” Cancer Research, vol. 68, no. 20, pp. 8384–8392, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. P. Gupta, D. M. Goldenberg, E. A. Rossi, and C.-H. Chang, “Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias,” Blood, vol. 116, no. 17, pp. 3258–3267, 2010. View at Publisher · View at Google Scholar
  99. J. P. Leonard, M. Coleman, J. C. Ketas et al., “Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 21, no. 16, pp. 3051–3059, 2003. View at Publisher · View at Google Scholar · View at Scopus
  100. J. P. Leonard, M. Coleman, J. C. Ketas et al., “Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results,” Clinical Cancer Research, vol. 10, no. 16, pp. 5327–5334, 2004. View at Publisher · View at Google Scholar · View at Scopus
  101. A. Younes, K. Hariharan, R. S. Allen, and B. R. Leigh, “Initial trials of anti-CD80 monoclonal antibody (galiximab) therapy for patients with relapsed or refractory follicular lymphoma,” Clinical Lymphoma, vol. 3, no. 4, pp. 257–259, 2003. View at Google Scholar · View at Scopus
  102. F. A. Vyth-Dreese, T. A. M. Dellemijn, D. Majoor, and D. De Jong, “Localization in situ of the co-stimulatory molecules B7.1, B7.2, CD40 and their ligands in normal human lymphoid tissue,” European Journal of Immunology, vol. 25, no. 11, pp. 3023–3029, 1995. View at Publisher · View at Google Scholar · View at Scopus
  103. J. M. Munro, A. S. Freedman, J. C. Aster et al., “In vivo expression of the B7 costimulatory molecule by subsets of antigen- presenting cells and the malignant cells of Hodgkin's disease,” Blood, vol. 83, no. 3, pp. 793–798, 1994. View at Google Scholar · View at Scopus
  104. J. P. Leonard, J. W. Friedberg, A. Younes et al., “A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma,” Annals of Oncology, vol. 18, no. 7, pp. 1216–1223, 2007. View at Publisher · View at Google Scholar · View at Scopus
  105. M. J. Keating, I. Flinn, V. Jain et al., “Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study,” Blood, vol. 99, no. 10, pp. 3554–3561, 2002. View at Publisher · View at Google Scholar · View at Scopus
  106. J. Lundin, H. Hagberg, R. Repp et al., “Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome,” Blood, vol. 101, no. 11, pp. 4267–4272, 2003. View at Publisher · View at Google Scholar · View at Scopus
  107. G. Enblad, H. Hagberg, M. Erlanson et al., “A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas,” Blood, vol. 103, no. 8, pp. 2920–2924, 2004. View at Publisher · View at Google Scholar · View at Scopus
  108. A. Gallamini, F. Zaja, C. Patti et al., “Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial,” Blood, vol. 110, no. 7, pp. 2316–2323, 2007. View at Publisher · View at Google Scholar · View at Scopus
  109. R. Stein, Z. Qu, S. Chen, D. Solis, H. J. Hansen, and D. M. Goldenberg, “Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab,” Blood, vol. 108, no. 8, pp. 2736–2744, 2006. View at Publisher · View at Google Scholar · View at Scopus
  110. P. Hillmen, A. B. Skotnicki, T. Robak et al., “Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia,” Journal of Clinical Oncology, vol. 25, no. 35, pp. 5616–5623, 2007. View at Publisher · View at Google Scholar · View at Scopus
  111. K. Dunleavy, T. White, N. Grant et al., “Phase 1 study of combination rituximab with apolizumab in relapsed/refractory B-cell lymphoma and chronic lymphocytic leukemia,” vol. 23, 2005, ASCO Meeting Abstract 6607. View at Google Scholar
  112. G. L. DeNardo, S. J. DeNardo, D. S. Goldstein et al., “Maximum-tolerated dose, toxicity, and efficacy of I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 16, no. 10, pp. 3246–3256, 1998. View at Google Scholar · View at Scopus
  113. R. Schnell, M. Dietlein, K. Schomäcker et al., “Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's lymphoma,” Onkologie, vol. 31, no. 1-2, pp. 49–51, 2008. View at Publisher · View at Google Scholar · View at Scopus
  114. D. Ma, M. R. McDevitt, E. Barendswaard et al., “Radioimmunotherapy for model B cell malignancies using Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies,” Leukemia, vol. 16, no. 1, pp. 60–66, 2002. View at Publisher · View at Google Scholar · View at Scopus
  115. T. E. Witzig, L. I. Gordon, F. Cabanillas et al., “Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 20, no. 10, pp. 2453–2463, 2002. View at Publisher · View at Google Scholar · View at Scopus
  116. T. E. Witzig, A. Molina, L. I. Gordon et al., “Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan,” Cancer, vol. 109, no. 9, pp. 1804–1810, 2007. View at Publisher · View at Google Scholar · View at Scopus
  117. F. Morschhauser, T. Illidge, D. Huglo et al., “Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation,” Blood, vol. 110, no. 1, pp. 54–58, 2007. View at Publisher · View at Google Scholar · View at Scopus
  118. P. L. Zinzani, M. Tani, S. Fanti et al., “A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients,” Annals of Oncology, vol. 19, no. 4, pp. 769–773, 2008. View at Publisher · View at Google Scholar · View at Scopus
  119. S. J. Horning, A. Younes, V. Jain et al., “Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab,” Journal of Clinical Oncology, vol. 23, no. 4, pp. 712–719, 2005. View at Publisher · View at Google Scholar
  120. M. S. Kaminski, M. Tuck, J. Estes et al., “131I-tositumomab therapy as initial treatment for follicular lymphoma,” New England Journal of Medicine, vol. 352, no. 5, pp. 441–449, 2005. View at Publisher · View at Google Scholar
  121. O. W. Press, J. M. Unger, R. M. Braziel et al., “Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group protocol S9911,” Journal of Clinical Oncology, vol. 24, no. 25, pp. 4143–4149, 2006. View at Publisher · View at Google Scholar · View at Scopus
  122. A. K. Gopal, J. M. Pagel, J. R. Fromm, S. Wilbur, and O. W. Press, “131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma,” Blood, vol. 113, no. 23, pp. 5905–5910, 2009. View at Publisher · View at Google Scholar · View at Scopus
  123. T. Witzig, C. Emmanouilides, A. Molina, L. Gordon, I. Gaston, and I. Flinn, “Yttrium-90 ibritumomab tiuxetan radioimmunotherapy (RIT) induces durable complete responses (CR/CRu) in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL),” Proceedings of the American Society of Clinical Oncology, vol. 22, p. 597, 2003. View at Google Scholar
  124. M. S. Kaminski, A. D. Zelenetz, O. W. Press et al., “Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas,” Journal of Clinical Oncology, vol. 19, no. 19, pp. 3918–3928, 2001. View at Google Scholar · View at Scopus
  125. M. S. Kaminski, M. Tuck, J. Estes et al., “131I-tositumomab therapy as initial treatment for follicular lymphoma,” New England Journal of Medicine, vol. 352, no. 5, pp. 441–449, 2005. View at Publisher · View at Google Scholar
  126. M. E. Juweid, E. Stadtmauer, G. Hajjar et al., “Pharmacokinetics, dosimetry, and initial therapeutic results with I- and In-/Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma,” Clinical Cancer Research, vol. 5, no. 10, pp. 3292s–3303s, 1999. View at Google Scholar · View at Scopus
  127. R. O’Donnell, G. DeNardo, D. Kukis et al., “67copper-2-iminothiolane-6-[p-(bromoacetamido) benzyl]-teta-lym-1 for radioimmunotherapy of non-hodgkin’s lymphoma,” Clinical Cancer Research, vol. 5, no. 10, p. 3330s, 1999. View at Google Scholar
  128. R. T. O'Donnell, G. L. DeNardo, D. L. Kukis et al., “A clinical trial of radioimmunotherapy with Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma,” Journal of Nuclear Medicine, vol. 40, no. 12, pp. 2014–2020, 1999. View at Google Scholar · View at Scopus
  129. E. Aurlien, R. H. Larsen, G. Kvalheim, and Ø. S. Bruland, “Demonstration of highly specific toxicity of the α-emitting radioimmunoconjugate 211At-rituximab against non-Hodgkin's lymphoma cells,” British Journal of Cancer, vol. 83, no. 10, pp. 1375–1379, 2000. View at Google Scholar
  130. S. Knop, A. Jakob, L. Kanz, H. Hebart, R. Bares, and B. Dohmen, “186Rhenium-labeled anti-CD20 antibody radioimmunotherapy followed by autologous peripheral blood stem cell transplantation in patients with relapsed or refractory non-Hodgkin lymphoma,” Blood, vol. 103, no. 3, p. 1175, 2004. View at Publisher · View at Google Scholar · View at Scopus